- Home
- MTN vs NAMS Comparison
MTN vs NAMS Comparison
Compare MTN & NAMS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | MTN | NAMS |
|---|---|---|
| Founded | 1997 | 2019 |
| Country | United States | Netherlands |
| Employees | N/A | 100 |
| Industry | Services-Misc. Amusement & Recreation | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.4B | 4.1B |
| IPO Year | 1996 | N/A |
Fundamental Metrics
Financial Performance| Metric | MTN | NAMS |
|---|---|---|
| Price | $141.86 | $30.63 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 12 | 8 |
| Target Price | ★ $162.58 | $46.75 |
| AVG Volume (30 Days) | 915.4K | ★ 1.1M |
| Earning Date | 06-04-2026 | 05-06-2026 |
| Dividend Yield | ★ 7.27% | N/A |
| EPS Growth | ★ 24.05 | N/A |
| EPS | ★ 9.43 | N/A |
| Revenue | ★ $2,964,347,000.00 | N/A |
| Revenue This Year | N/A | $17.96 |
| Revenue Next Year | $6.42 | $540.65 |
| P/E Ratio | $15.35 | ★ N/A |
| Revenue Growth | ★ 2.74 | N/A |
| 52 Week Low | $118.51 | $17.97 |
| 52 Week High | $172.00 | $42.21 |
Technical Indicators
Market Signals| Indicator | MTN | NAMS |
|---|---|---|
| Relative Strength Index (RSI) | 60.26 | 42.25 |
| Support Level | $136.74 | $30.34 |
| Resistance Level | $144.63 | $31.72 |
| Average True Range (ATR) | 5.96 | 1.60 |
| MACD | 0.60 | -0.16 |
| Stochastic Oscillator | 72.82 | 30.98 |
Price Performance
Historical ComparisonAbout MTN Vail Resorts Inc.
Vail Resorts Inc Bhd is a resorts and casinos company that operates mountain resorts and ski areas. The company has three business segments that include Mountain, Lodging, and Real Estate. The Mountain segment operates numerous ski resort properties that offer a variety of winter and summer activities, such as skiing, snowboarding, snowshoeing, hiking, and mountain biking. The Lodging segment owns and operates hotels and condominiums. The Real Estate segment owns, develops, and leases real estate, typically near its other properties. The company generates the vast majority of its revenue within the United States.
About NAMS NewAmsterdam Pharma Company N.V.
NewAmsterdam Pharma Co NV is a late-stage biopharmaceutical company with a mission to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. Its product, obicetrapib, is a next-generation, oral, low-dose CETP inhibitor that is developed to potentially overcome the limitations of current LDL-C lowering treatments. The Company has one reportable segment, which comprises the discovery, development, and commercialization of transformative therapies for cardio-metabolic diseases.